Multicenter phase II trials with Gemtuzumab Ozogamicin (GO/ Mylotarg s ), consisting of a CD33 antibody linked to the cytotoxic drug calicheamicin, have shown a 30% overall response rate in relapsed acute myeloid leukemia patients. However, no clear correlation was observed between CD33 expression on leukemic blasts and response to GO therapy. We analyzed the CD33 specificity of GO-induced cell death and the effect of GO on CD33-negative malignancies. We demonstrate that lysis induced by clinically relevant GO concentrations is partially CD33 mediated, and that efficient non-CD33-mediated GO uptake can occur via endocytosis. In agreement with these results, we observed GO-mediated death of human CD33-negative acute lymphoblastic leukemia cells both in vitro and in vivo in an NOD/SCID mouse model. Finally, sensitivity to GOinduced cell death was at least partially determined by the activation status of leukemic cells, with cells in activated phases of the cell cycle being most effective in both CD33-specific GO internalization, renewed expression of CD33 molecules, and non-CD33-mediated GO uptake via endocytosis. In conclusion, these data provide mechanistic insight into the efficacy of GO in CD33-positive as well as in CD33-negative malignancies with endocytic capacity, and provide a rationale for the use of GO in the treatment of malignancies with endocytic capacity.
Introduction
The treatment of choice for patients with acute myeloid leukemia (AML), below 60 years of age, is high-dose chemotherapy followed by allogeneic or autologous stem cell transplantation. 1 Approximately 70-80% of the patients achieve a complete remission after high-dose chemotherapy, but relapses occur frequently, 2 resulting in an overall disease-free survival of only 35% of all patients.
Antibody-targeted chemotherapy is a promising new therapy introduced for the treatment of relapsed or refractory AML patients. 3 The purpose of this therapy is to deliver chemotherapeutic agents to the target cells selectively by conjugation to a monoclonal antibody that targets leukemic cells, thereby diminishing the toxic side effects and probably the treatmentrelated morbidity and mortality. 4, 5 CD33, a 67 kDa glycoprotein, 6 which is normally expressed during myeloid differentiation, is expressed on leukemic blasts in 90% of patients with AML, 7, 8 but is not expressed on normal hematopoietic stem cells or nonhematopoietic tissues. 9, 10 Gemtuzumab Ozogamicin (GO, Mylotarg s , CMA-676) 11, 12 used for the treatment of patients with AML consists of a humanized CD33 antibody (clone P67.6), which is coupled to the cytotoxic agent calicheamicin via a linker that is stable in the extracellular compartments, but hydrolyzed inside the cells. 11, 12 Binding of GO to CD33 on the membrane results in rapid internalization followed by the release of the calicheamicin. 13 Similar to the conventionally used cytotoxic agent daunorubicin, calicheamicin is an anthracyclin that probably acts by binding to the minor groove of DNA and introduction of double-strand DNA breaks. 14, 15 Multicenter phase II trials have shown a 30% overall response rate in relapsed AML patients. 16, 17 Surprisingly, similar to the results obtained by others, 18 in the cohort of AML patients treated with GO in our institute, we observed no clear correlation between the CD33 expression on the leukemic blasts and the response to therapy (Table 1) . Based on these observations, we hypothesized that GO exerts its clinical effect not only via CD33-specific internalization but also via alternative uptake mechanisms as well.
The assumption of nonspecific GO uptake mechanisms would suggest major toxicity in patients treated with GO. However, the observed toxicity appeared to be limited and restricted to certain target organs, 19, 20 suggesting a certain specificity of GO other than CD33 specificity. In previous studies, we demonstrated the importance of the cell cycle status of leukemic cells in sensitivity to conventional chemotherapy regimens. The sensitivity to the anthracyclin daunorubicin was found to be specific for activated cells in the G 1 and cycling S or G 2 /M phase, 21 with cells in the resting G 0 phase of the cell cycle being resistant to conventional chemotherapeutic agents. Therefore, we hypothesized that the activation status of leukemic cells, as defined by their cell cycle status, influences the sensitivity to GO and thereby adds to the specificity of GO, explaining the limited aspecific toxicity.
We studied the CD33 specificity of GO-induced cell death, the pathways of GO uptake, and the effect of GO on CD33-negative leukemic cells. In addition, we analyzed whether, similar to conventional chemotherapy, the cell cycle status of leukemic cells influences the sensitivity of the cells to GO.
Our results demonstrate two different GO internalization mechanisms. A CD33-specific internalization mechanism and a CD33-independent uptake mechanism, probably via endocytosis. Via the CD33-independent uptake mechanism, GO is able to kill CD33-negative leukemic cells with endocytic capacity. Both GO uptake mechanisms are significantly influenced by the cell cycle status of the target cells, with cells in the resting G 0 phase being less efficient in executing both processes. Using an in vivo model of human acute lymphoblastic leukemia (ALL) in NOD/SCID mice, 22 we illustrate that ALL can be an appropriate target for GO-mediated therapy. In conclusion, our results provide mechanistic insight into the efficacy of GO in CD33-negative malignancies, and provide a rationale for the use of GO in the treatment of CD33-positive as well as CD33-negative malignancies with endocytic capacity.
Materials and methods

Cell lines
The human acute promyelocytic leukemia cell line HL-60 and the human granulocyte/macrophage colony-stimulating factor (GM-CSF)-dependent AML cell line AML-193 23 were obtained from the American Type Culture Collection (Rockville, MD, USA). The human acute lymphoblastic leukemia (ALL) cell lines Leiden-ALL-HP, Leiden-ALL-RL, Leiden-ALL-PH, and Leiden-ALL-SK were generated in our laboratory from four different ALL patients by culturing sorted patient ALL blasts in serum-free medium.
All cell lines were cultured in serum-free medium consisting of IMDM (BioWhittaker, Verviers, Belgium) supplemented with 3 mM L-glutamine (BioWhittaker), antibiotics, 0.4% human serum albumin (HSA) (wt/vol) (CLB, Amsterdam, The Netherlands), 20 mg/ml cholesterol (Sigma-Aldrich, Zwijndrecht, The Netherlands), 2 mg/ml transferrin (Serva, Heidelberg, Germany), 5 Â 10 À5 M b-mercaptoethanol (Sigma-Aldrich), and 10 mg/ml insulin (Sigma-Aldrich).
AML-193 cell line and culture conditions
AML-193 cells were cultured at 371C and 5% CO 2 in serum-free medium. The addition of 20 ng/ml recombinant human GM-CSF (Novartis, Basle, Switzerland) to the culture medium was shown to induce persistent proliferation in these cells. An additional AML-193 subcell line was generated by culturing for at least 2 weeks in a medium containing 1000 U/ml interferon-gamma (IFN-g) (Strathmann Biotech, Hannover, Germany). 24 These cell lines were expanded in a medium containing 20 ng/ml GM-CSF. Growth factor deprivation of these lines was performed by washing the cells three times with phosphate-buffered saline (PBS), and subsequent culturing for at least 3 days in serum-free culture medium without GM-CSF.
Patients
Of all patients who received GO in our institute before May 2001, we studied retrospectively the correlation between CD33 expression on the leukemic blasts and the response to treatment. All 12 patients received GO according to an EORTC leukemia protocol (Amadori et al. Blood 2002; 100: 340a; abstract). Patient characteristics are summarized in Table 1 . GO was administered as a 2-h intravenous (i.v.) infusion at a dose of 9 mg/m 2 . Two patients received a single dose, whereas 10 patients received a second dose 14-18 days after the first dose. Leukemic blasts were phenotyped via standardized procedures in a certified morphology lab using leukemia-specific markers.
Cytotoxicity assay
The cytotoxic activity of GO was tested in 24 and 40 h 51 Cr release assays. 24 Target cells were labeled with 100 mCi of Na 2 51 CrO 4 (Amersham, Freiburg, Germany) for 60 min at 371C, washed two times with IMDM supplemented with 0.1% HSA, and resuspended in serum-free culture medium at a concentration of 2.5 Â 10 5 cells/ml. A volume of 100 ml target cells was added to 100 ml serum-free culture medium, containing different concentrations of GO (Wyeth, St Davids, PA, USA) ranging from 1.25 to 10 mg/ml in 96-well U-bottom plates. In some experiments, various concentrations of the active calicheamicin derivative N-acetyl gamma calicheamicin dimethyl hydrazide (NAc-gamma DMH, Wyeth) ranging from 0.01 to 0.5 mg/ml were added to the cells. The cells were incubated in a humidified atmosphere of 5% CO 2 and 371C, after 24 h, 25 ml of supernatant was harvested on solid scintillator-coated lumaplates (Packard, Groningen, The Netherlands), and counted in an automatic gamma counter (Topcount, Packard). Plates were then incubated for another 16 h (40 h assay), and again 25 ml of supernatant was harvested and counted. For each target cell type, spontaneous release as well as maximal release were determined. Percentage of lysis was calculated as follows:
%specific lysis ¼ experimental release ðcpmÞÀspontaneous release ðcpmÞ maximal release ðcpmÞÀspontaneous release ðcpmÞ Â100
CD33 blocking experiments were performed by preincubation of 51 Cr-labeled CD33-positive AML-193 cells with excess concentrations of 50 or 500 mg/ml unconjugated hP67.6 antibodies (Wyeth), respectively, 100 and 1000 times the 
In vivo mouse experiments
Female NOD/SCID mice aged 5-6 weeks were obtained from Bomholtgaard Breeding and Research Center (Ry, Denmark). Animals were housed in sterile cages individually supplied with sterile filtered air (Tecnilab/BMI, Someren, the Netherlands). Mice were engrafted with human leukemia and monitored as described previously. 22 In short, 10 7 Leiden-ALL-RL cells were injected i.v. in 200 ml IMDM supplemented with 2% fetal calf serum (Bio Whittaker, Verviers, Belgium). To monitor leukemic progression, 50 ml peripheral blood samples were taken at regular intervals. The total nucleated cell counts (NCCs) were determined by automated counting in a Sysmex F-800 microcellcounter (Sysmex Corp., Kobe, Japan). The percentage of human cells (%Hu) was determined using flowcytometric analysis by double staining of the samples with an FITC-labeled human CD45 antibody (BD, San Jose, CA, USA) and a PE-labeled murine CD45 antibody (Ly5; Pharmingen, San Diego, CA, USA). Leukemic cell counts (LCCs) were calculated as LCC (10 6 /ml) ¼ NCC (10 6 /ml) Â %Hu. After 3 weeks, human leukemic cells were detected in the blood of the mice. After 2 weeks, the mice received the first GO treatment, which was repeated 2 weeks later. GO was administered in 200 ml of sterile phospate-buffered saline i.v. in the lateral tail vein.
Fluorescence microscopy
To determine the capacity of different cell types to internalize antibodies, the cells were incubated for 16 h in culture medium at 371C in the presence of FITC-labeled CD33 antibodies (CLB, Amsterdam, The Netherlands). After washing with PBS, cells were fixed for 15 min with paraformaldehyde, washed, and cytospins were made. Cytospin slides were embedded with 20 ml of Citifluor (AF1; Agar Scientific, Zaandam, The Netherlands) containing 0.05 mg/ml 4 0 , 6 0 -diamino-2-phenylindoldihydrochloride (DAPI) for nuclear staining. Slides were analyzed by fluorescence microscopy. As a control, cells were incubated with either CD33-FITC, or FITC-labeled CD19 or mouse IgG1 isotype antibodies (BD) at 41C for 30 min, resulting in staining of membrane antigens without subsequent internalization.
Cell cycle analysis
For cell cycle analysis, 10 6 cells were washed with PBS, fixed, and permeabilized with 1% paraformaldehyde and 80 mg/ml Lalpha-lysolecithin (Sigma-Aldrich) for 10 min at 41C, washed with PBS/HSA, and stained with an anti-ki-67 monoclonal antibody (clone MIB-1; Dako, Glostrup, Denmark) for 30 min at 41C. The cells were subsequently stained with FITC-labeled goat-anti-mouse antibodies (BD). Isotype controls were stained in parallel. Cells were washed, incubated with 20 mg/ml RNAse (Sentra Systems, Minneapolis, USA) for 15 min at 371C, stained with 20 mg/ml propidium iodide (PI) in PBS, and flowcytometric analysis was performed. The percentages of cells in each fraction of the cell cycle were calculated by CellQuest software (BD). To analyze cell cycle-specific apoptosis induction, 3 Â 10 6 cells were seeded in a total volume of 5 ml in six-well plates, and incubated in a culture medium containing various cytokines in the presence or absence of 5 mg/ml GO or 0.1 mg/ml of the free calicheamicin derivative. After 0, 24, and 40 h, the cells were harvested, cell cycle analysis of the viable cells was performed, and the percentages of cells in each cell cycle fraction (G 0 , G 1 , S, and G 2 /M) were calculated.
Saturation and modulation assays
The levels of CD33-specific GO internalization, and the renewed expression of free CD33 molecules were determined as described earlier. 13 Briefly, the amount of GO bound to the cells was measured using biotin-conjugated mouse-antihuman IgG4 antibodies (Caltag Laboratories, Burlingame, CA, USA), followed by streptavidin-FITC (Biosource, Nivelles, Belgium) staining. To determine the maximal possible GO binding (100% saturation), cells were first incubated with an excess of GO (final concentration 10 mg/ml), followed by subsequent incubation with biotin-conjugated mouse-anti-human IgG4 antibodies, and streptavidin-FITC. All incubations were performed for 20 min at 41C to avoid internalization during the staining period.
To determine specific internalization of GO, as defined by GO downmodulation from the cell surface, AML-193 cells were continuously exposed to 5 mg/ml GO at 371C for different periods of time. Downmodulation was defined as 1-(specific fluorescence intensity of the maximal GO binding at time point x)/(specific fluorescence intensity of the maximal GO binding at time point 0) Â 100%, in which time point 0 is the time point immediately prior to GO exposure.
To determine the levels of renewed expression of free, non-GO-bound CD33 molecules on the cell surface after internalization of the GO-CD33 complex, AML-193 cells were pulse labeled for 15 min at 371C with 5 mg/ml GO, after which non-bound antibody was removed by washing the cells with culture medium. The cells were resuspended and incubated for different periods of time to allow the cells to internalize GO, followed by subsequent analysis of CD33 saturation. Saturation was defined as (specific fluorescence intensity of bound GO at time point x)/(specific fluorescence intensity of the maximal GO binding at time point x) Â 100%. Renewed expression of free non-GO-bound CD33 molecules was defined as the decrease in GO saturation levels in time.
Dextran-FITC analysis of endocytic capacity
The endocytic capacity of cells was measured by means of dextran-FITC uptake, as described previously. 25 Briefly, 2 Â 10 5 cells were resuspended in culture medium and cultured for 15 min at 371C. Subsequently, 1 mg/ml dextran-FITC (Polysciences Inc., Warrington, PA, USA) was added and samples were incubated for 2 h at 371C. Negative control samples were incubated with dextran-FITC for the same period of time at 41C. The reaction was stopped with cold PBS-HSA. Cells were washed three times with PBS-HSA and analyzed on a BD flowcytometer. The mean fluorescence intensities (MFIs) were determined, and the ratio between the MFI 371C and the MFI 41C was calculated, representing the level of specific dextran-FITC uptake.
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Results
CD33 specificity of GO-induced cell death
In a series of AML patients treated with GO in our institute, we observed no correlation between response rates and CD33 expression ( Table 1) . Twelve AML patients received one or two cycles of GO. In this cohort of patients, we achieved five complete responses, two partial responses, and five patients were refractory to the treatment. No correlation was observed between the CD33 expression on the leukemic blasts and the response to treatment. To test the hypothesis that GO could exert its clinical effect not only via a CD33-specific uptake mechanism but also via alternative uptake mechanisms, we explored the effect of blockade of CD33 on AML-193 cells on the sensitivity to GO-induced cell death. CD33-positive AML-193 cells were preincubated with excess concentrations (50 or 500 mg/ml) of unconjugated CD33 (hP67.6) antibodies prior to exposure of the cells to various GO concentrations. As shown in Figures 1a and b , without the blockade of CD33 molecules, GOinduced cell death ranged from 1273% lysis (1 mg/ml GO) to 3273% (10 mg/ml GO) after 24 h and from 25718 to 68715% after 40 h of GO incubation. The results of CD33 blockade with either 50 or 500 mg/ml hP67.6 antibodies are shown in Figure 1a and b. Figure 1c summarizes the inhibitory effect of CD33 blockade on GO-induced lysis. The complete inhibition of lysis was induced at the lowest GO concentration of 1 mg/ml. However, only half of the lysis induced by 3 mg/ml GO, which equals the average serum concentration measured in the peripheral blood of patients treated with GO, 11, 26 could be inhibited by CD33 blockade, with 49714 and 40712% inhibition after 24 and 40 h, respectively. At higher GO concentrations, CD33 blockade using 500 mg/ml hP67.6 antibodies resulted in only marginal inhibition of lysis of 24719 and 21713% at 5 mg/ml GO after 24 and 40 h, respectively, or no inhibition at 10 mg/ml GO. These results suggest two GO uptake mechanisms, comprising CD33-specific GO uptake at lower GO concentrations, and additional CD33-independent uptake at higher GO concentrations.
CD33-independent GO effects in CD33-negative ALL cells
To further analyze the presence of alternative non-CD33-mediated GO uptake mechanisms, we tested whether GO was able to induce cell death in cells lacking clear surface CD33 expression. Figure 2a illustrates the analysis of CD33 expression on the cell surface of three ALL cell lines generated in our laboratory by flowcytometric analysis using PE-labeled CD33 antibodies. Although in these cell lines low levels of CD33 mRNA expression were detected by quantitative real-time PCR comparable to baseline mRNA expression in normal B and T cells (data not shown), no CD33 expression on the cell surface could be demonstrated. Figure 2b shows the results of 51 Cr release experiments performed in triplicate in which the CD33-negative ALL cell lines were exposed to GO concentrations ranging from 1 to 10 mg/ml. After 24 h of GO exposure, 20-55% specific lysis was observed. To investigate whether this GOinduced lysis was possibly mediated via binding to low levels of CD33 expression that were below the detection level of flowcytometric analysis, excess concentrations of uncoupled CD33 hP67.6 Ab (500 mg/ml) were added to the cells prior to incubation with GO. No decrease in the amount of lysis was observed after CD33 blockade, illustrating that the GOinduced cell death of these phenotypically CD33-negative ALL cell lines was mediated via CD33-independent GO uptake mechanisms.
In vivo GO effect on CD33-negative ALL cells
To exclude the possibility that the observed CD33-independent GO uptake was only an in vitro artifact, we explored the in vivo CD33 specificity of GO-induced cell death in CD33-positive AML-193 cells. Cells were preincubated with either 50 or 500 mg/ml unconjugated hP67.6 antibodies prior to exposure to increasing GO concentrations, ranging from 1 to 10 mg/ml. The percentages of lysis after 24 (a) and 40 h (b) are plotted for each GO concentration in the absence (E) or in the presence of 50 (K) or 500 (') mg/ml hP67.6 antibodies (n ¼ 4). (c) The percentage inhibition of lysis induced by CD33 blockade is plotted for each GO concentration after 24 h (# and ") and 40 h (' and &) of GO treatment in the presence of, respectively, 50 and 500 mg/ml hP67.6 antibodies, n ¼ 4.
Efficacy of GO in CD33-negative malignancies I Jedema et al efficacy of GO treatment on CD33-negative malignancies in the NOD/SCID mouse model. 22 NOD/SCID mice were inoculated with human CD33-negative ALL cells. After 40 days, mice were treated with 10, 25, or 50 mg of GO (Figure 3) . After 2 weeks, the mice received a second dose of GO of 10, 25, or 50 mg. Untreated control mice showed exponential leukemic cell growth and were moribund due to leukemic progression. Treatment with 10 mg of GO resulted in marginal inhibition of the leukemic cell growth and progression of the disease occurred. Treatment with 25 mg significantly reduced the number of leukemic cells in the peripheral blood, but eventually massive relapse occurred 19 days after the second GO dose. The highest dosage of 50 mg GO induced deletion of the leukemic cell population from the peripheral blood of the mice after both administrations. These data illustrate that GO is able to induce the elimination of CD33-negative leukemic cells both in vitro and in vivo.
CD33-independent uptake of antibodies by ALL cells
To further unravel the mechanism of CD33-independent GO uptake, and to exclude the possibility that the GO-induced lysis observed in the CD33-negative ALL cells was caused by uptake of free calicheamicin rather than uptake of the whole GO complex, fluorescence microscopy experiments were performed to investigate the ability of the ALL cells to internalize FITClabeled antibodies. Figure 4a shows the absence of surface CD33 expression on the ALL cells after Ab staining for 30 min at 41C. DAPI staining was used to visualize the nuclei. Uptake of FITC-labeled CD33 antibodies as determined by cytoplasmic staining was observed in all three ALL cell lines after incubation for 16 h at 371C (Figure 4b ). Figure 4c shows the positive control for surface staining on these ALL cells with CD19-FITC antibodies. In addition, when the cells were incubated for 16 h at 371C with FITC-labeled mouse IgG1 isotype antibodies, similar cytoplasmic staining could be observed as demonstrated for CD33 (data not shown). These results demonstrate the ability of ALL cells to internalize antibodies via a receptor-independent mechanism.
Cell cycle specificity of GO
Since the clinically observed toxicity is limited compared to the degree of toxicity that could be anticipated if all cells capable of executing endocytosis would be susceptible to the lytic effects of GO, we hypothesized that alternative mechanisms would influence that specificity and toxicity of GO. Previous studies have shown the sensitivity to conventional chemotherapy is specific for leukemic cells in the activated G 1 , S, and G 2 /M phases of the cell cycle. 21 To investigate whether the activation status of leukemic cells influences the sensitivity to GO-induced cell death in a similar way, we studied in two CD33-positive AML and four CD33-negative ALL cell lines the cell cycle distribution of viable cells after 48 h of incubation in the presence or absence of 5 mg/ml GO using combined ki-67-FITC staining and PI DNA staining. Ki-67 is a nuclear protein that is present in cells in the activated G 1 , S, and G 2 /M phases of the cell cycle, but absent in resting cells in the G 0 phase. [27] [28] [29] [30] [31] Figure 5a shows the cell cycle distribution of the leukemic cells incubated in medium alone, discriminating cells in the resting G 0 phase (lower left quadrant), cells in the activated G 1 phase (lower right quadrant), and cycling cells in the S or G 2 /M phase of the cell cycle (upper right quadrant). After 48 h of GO exposure (Figure 5b) , deletion of the majority of cells from the activated G 1 , S, and G 2 /M compartments was observed in all cell lines, indicating that cells in the resting G 0 phase of the cell cycle were relatively protected against GO-induced cell death. These results indicate the specificity of GO-induced cell death for activated leukemic cells, independent of the CD33 expression. 
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Figure 2
GO-induced cell death in CD33-negative ALL cells. (a) The absence of CD33 expression on these ALL cells was demonstrated by flowcytometry using FITC-labeled anti-CD33 antibodies (solid lines) and isotype control antibodies as negative control (dashed lines). (b) These CD33-negative ALL cell lines were exposed for 24 h to GO in concentrations ranging from 1 to 10 mg/ml, either without (') or after preincubation with 500 mg/ml hP67.6 antibodies (&). The percentages of specific lysis were determined (n ¼ 2). 
Days after first GO administration
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Effect of activation and proliferative status manipulations on sensitivity to GO-induced cell death
To study whether it was possible to influence the GO sensitivity of leukemic cells by manipulation of their activation state, we used as a model the GM-CSF-dependent leukemic cell line AML-193 in the presence or absence of IFN-g, as described previously. 21, 24 In this model, it is possible to manipulate the proliferation and activation status of the cells separately. Figure 6a shows the activation status, as defined by the cell cycle distribution of AML-193 cells cultured under different activator conditions. In GM-CSF-deprived control AML-193 cells, the majority (6675%; n ¼ 15) of the cells was in the resting G 0 phase. The activation by IFN-g treatment without the induction of proliferation resulted in the recruitment of cells from the resting G 0 phase into activated phases of the cell cycle, leaving only 4874% of the cells in the resting G 0 phase (Po0.001; n ¼ 15). The induction of proliferation by GM-CSF treatment resulted in only 2178% of the cells residing in the G 0 phase, which was not further altered by additional IFN-g treatment. Figure 6b illustrates the effect of activation and proliferative status manipulations on the sensitivity to GOinduced cell death. Incubation of control cells with 1.25 mg/ml GO resulted in a median percentage specific lysis of 17% after 24 h (n ¼ 20). Stepwise increment of the dosage GO to 10 mg/ml resulted in only a limited increase in cell death to 31% lysis. Activation without induction of proliferation of control cells by IFN-g treatment was sufficient to increase significantly the susceptibility to GO, resulting in 28% lysis by 1.25 mg/ml GO increasing to 44% lysis by 10 mg/ml GO (Po0.001; n ¼ 20). The induction of proliferation by GM-CSF treatment did not significantly increase the sensitivity to 1.25 mg/ml GO. However, higher GO concentrations significantly increased the lysis of GM-CSF-stimulated cells, resulting in 49% lysis by 10 mg/ml GO (Po0.0001; n ¼ 20). Further activation of these proliferating cells by IFN-g treatment resulted in a further 15% increase in GO sensitivity (Po0.002). These results further demonstrate an association between the activation status of leukemic cells as measured by cell cycle distribution and GO-induced cell death. Receptor-independent internalization of antibodies by ALL cells. Three CD33-negative, CD19-positive ALL cell lines Leiden-ALL-HP, Leiden-ALL-PH, and Leiden-ALL-RL were analyzed by fluorescent microscopy after labeling with CD33 antibodies for 30 min at 41C (a) or after incubation for 16 h in the presence of CD33 antibodies at 371C (b) to study internalization. As a control for surface staining of ALL cells, these cells were labeled for 30 min at 41C with FITC-labeled CD19 antibodies (c). DAPI staining was used to stain the nuclei.
AML-193
HL-60 Figure 5 Cell cycle specificity of GO in leukemic cell lines. After 48 h of incubation in (a) medium alone, or (b) medium containing 5 mg/ml GO cell cycle analysis of viable cells was performed by PI/ki-67 analysis. Cells in G 0 (lower left compartment), G 1 (lower right compartment) and S/G 2 /M (upper right compartment) phases of the cell cycle could be discriminated.
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Correlation between activation status of leukemic cells and CD33-specific internalization, CD33-independent uptake, and CD33 re-expression To investigate whether the specificity of GO-induced cell death for activated leukemic cells was associated with the ability of the cells to either CD33 specifically or independently internalize GO, we determined the levels of CD33-specific GO downmodulation from the cell surface in AML-193 cells, and analyzed the capacity of the cells to renew the expression of non-GO-bound CD33 molecules on the cell surface. 13 In order to assay the ability of the cells to take up GO via alternative pathways, we determined the endocytic capacity by means of dextran-FITC uptake. Figure 7a demonstrates that the CD33 receptor expression on AML-193 cells was not affected by the activation steps. Figure 7b shows the ability of resting and activated AML-193 cells to internalize GO as measured by the amount of specific CD33 downmodulation from the cell surface after 6 h of continuous GO exposure. Exposure of resting control AML-193 cells to 5 mg/ml GO resulted in 31% (n ¼ 5; 
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Figure 7
The influence of cell cycle status on CD33-specific internalization, renewed expression of empty CD33 molecules, and endocytic capacity. The CD33 expression after cell cycle manipulations within AML-193 cells was determined by flowcytometry using PE-labeled CD33 antibodies (solid lines) and isotype control antibodies as negative control (dashed lines) (a). CD33-specific internalization was measured by modulation of GO from the cell surface after 6 h of GO exposure by comparing the maximal GO binding at each time point with the maximal GO binding just before the GO exposure. The levels of renewed expression of empty CD33 molecules after internalization was determined as the decrease in saturation levels in time after pulse-labeling with GO (b). The endocytic capacity of the cells was determined by dextran-FITC uptake in 2 h at 371C (c, solid lines). Dashed lines visualize the negative controls incubated at 41C.
Efficacy of GO in CD33-negative malignancies I Jedema et al (n ¼ 5) of the surface CD33 was non-GO-bound 6 h after GO pulse labeling, as compared to activated cells (26% in IFN-gtreated cells (n ¼ 2), 24% in GM-CSF-treated cells (n ¼ 5) and 25% in GM-CSF þ IFN-g-treated cells (n ¼ 5)). The effect of cell cycle status on the endocytic capacity of AML-193 cells was measured by means of the dextran-FITC uptake (Figure 7c ). Resting control AML-193 cells showed some dextran-FITC uptake (ratio 1.81). Activation of the cells by IFN-g or induction of proliferation with GM-CSF significantly increased the level of dextran-FITC uptake (ratios of 3.07 and 3.09, respectively). IFN-g treatment of proliferating GM-CSFtreated cells further increased the level of dextran-FITC uptake (ratio 3.56).
These data indicate that the efficiency of both CD33-specific GO internalization, non-CD33-mediated endocytic GO uptake, as well as the renewed CD33 expression are determined by the activation status of the target cell population.
Correlation between activation status of leukemic cells and sensitivity to the active calicheamicin derivative
To investigate whether, in addition to the efficiency of the CD33-specific internalization and non-CD33-mediated endocytic uptake of GO, the activation status of leukemic cells also determined the sensitivity to the chemotherapeutic part of GO, the active calicheamicin derivative NAc-gamma DMH, we performed toxicity assays and cell cycle analysis after exposure of resting and proliferating AML193 cells to NAc-gamma DMH.
The 24 h dose-response curve of calicheamicin-induced cell death was significantly lower in resting control AML-193 cells as compared to proliferating GM-CSF AML-193 cells, suggesting similar cell cycle specificity as observed in previous studies with daunorubicin 21 (Figure 8a ). Figure 8b illustrates the cell cycle analysis of activated AML-193 cells incubated for 24 h either in medium alone or in a medium containing 0.1 mg/ml calicheamicin, resembling the amount of active calicheamicin that is released by 3.25 mg/ml GO. Clear enrichment for cells in the resting G 0 phase was observed after exposure to calicheamicin, illustrating specific deletion of activated cells.
Discussion
Antibody-mediated chemotherapy is a promising new strategy in the treatment of AML designed to increase the treatment specificity. However, similar to the results obtained by others 17, 18 in the cohort of AML patients treated with GO in our institute, no clear correlation was observed between the CD33 expression levels on the leukemic blasts and the response to treatment (Table 1) .
In this report, we show that GO may exert its effect not only via CD33-specific internalization but also via endocytosis. Using the AML-193 cell line as a model, we studied GOinduced cell death using a range of GO concentrations, based on the average GO concentration of approximately 3 mg/ml measured in the serum of AML patients after GO infusion. 11, 26 Using blocking CD33 antibodies tested at 100 and 1000 times, the concentration needed to achieve complete CD33 saturation, we demonstrated complete CD33-mediated specificity of GO only at the lowest GO concentration tested (1 mg/ml). In contrast, the lysis induced by higher GO concentrations appeared to be only partially CD33 specific (Figure 1) . The biological relevance of the CD33-independent GO uptake was demonstrated in CD33-negative ALL cell lines generated in our laboratory, closely resembling primary ALL. These CD33-negative ALL cells were killed after exposure to GO at similar concentration ranges used for AML treatment. Since low mRNA levels of CD33 could be detected by PCR, we analyzed whether low membrane expression of CD33 that could not be detected using flowcytometric analysis was responsible for the efficacy of GO in these cells. However, blocking studies using saturating excess CD33 antibodies identical to the CD33 compound of GO illustrated that specific binding of GO to CD33 on the cell membrane was not required for its toxicity in these ALL cell lines. To exclude the possibility that the CD33-independent GO uptake was just an in vitro artifact, the in vivo effect of GO on the CD33-negative ALL cells was tested in an NOD/SCID mouse model for human acute lymphoblastic leukemia as described earlier. 22 Treatment with GO resulted in partial dose-dependent inhibition of leukemic cell growth in vivo, with complete eradication of leukemia from the blood by the highest GO dose, demonstrating the biological relevance and possible clinical potential of GO treatment of CD33-negative malignancies.
In order to further unravel the mechanism of CD33-independent GO uptake and to test whether the GO toxicity observed in CD33-negative cells could be explained by free calicheamicin rather than via uptake of the whole GO complex, we studied the ability of CD33-negative ALL cells to take up antibodies by fluorescence microscopy. The ALL cells could indeed take up FITC-labeled CD33 antibodies, a phenomenon that appeared not to be specific for CD33 antibodies, but could also be demonstrated for mouse isotype control antibodies (data not shown). To determine whether the CD33-unrelated GO-induced toxicity was mediated via Fc receptors on the cell surface, we preincubated both CD33-positive and CD33-negative cells with excess concentrations of free Cr release assay (a). After 24 h of incubation in medium alone or medium containing 0.1 mg/ml free calicheamicin, cell cycle analysis of viable cells was performed by PI/ki-67 analysis to determine the cell cycle specificity (b).
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In efforts to explain the relatively low clinical toxicity at the GO concentrations used, we hypothesized that mechanisms besides CD33 specificity influenced the specificity of GOinduced cell death. In previous studies, we demonstrated the specificity of conventional chemotherapeutic agents for activated leukemic cells in activated G 1 , S, and G 2 /M phases of the cell cycle, and resistance of resting leukemic cells in the G 0 phase. 21 Therefore, we investigated in detail the influence of cell cycle status of leukemic cells on both the sensitivity to GO and the ability of the cells to internalize the complex. Similar to the results obtained with the conventional chemotherapeutic agent daunorubicin, GO-induced cell death appeared to be specific for cells in activated G 1 , S, or G 2 /M phases of the cell cycle, whereas cells in the noncycling resting G 0 phase of the cell cycle were relatively resistant. This specificity was independent of the uptake pathway used, since similar results were obtained in both CD33-positive and -negative leukemic cells. In contrast, the study of Naito et al 32 visualized a clear S/G 2 /M arrest after 48 h of exposure to GO. We observed a similar phenomenon only at very low GO concentrations (1-100 ng/ml), which did not induce leukemic cell death. Exposure of leukemic cells to clinically obtained concentrations of 1-10 mg/ml of GO always resulted in deletion of activated cells.
To study the effect of activation status manipulations on GO sensitivity, we used a model that we have described earlier using the AML-193 cell line, in which we could manipulate separately the activation status and the proliferative status of the cells, using GM-CSF and long-term IFN-g treatment. 24 These cell cycle manipulations did not affect either CD33 expression or the expression levels of apoptosis-related markers like Fas, TNF-R1, Bax, and Bcl-2. 24 However, the fraction of cells in activated phases of the cell cycle strongly correlated with the sensitivity to GO, in a similar way as observed with the calicheamicinanalogue daunorubicin, 21 suggesting that the specificity of GO for activated cells is primarily determined by the calicheamicin part. However, the additional effect on GO sensitivity of IFN-g treatment in the presence of GM-CSF (Figure 6b ) could not be explained by the fraction of activated cells (Figure 6a ). IFN-g treatment of GM-CSF-treated cells additionally increased endocytic capacity as measured by dextran-FITC uptake, 25 possibly reflecting the increased capacity of these cells to CD33 independently take up GO (Figure 7c) . Also, the ability of AML-193 cells to CD33 specifically internalize GO and the capacity to renew the expression of empty CD33 molecules on the cell surface correlated with the activation status of the cells. In addition to the effect on the capacity of the cells to internalize GO, the activation status of the cells also determined the sensitivity to the active calicheamicin derivative (Figure 8) .
Our results may also in part explain the toxic side effects observed in some of the patients treated with GO. It may be speculated that the toxicity observed after GO treatment in some patients is caused by liver cells taking up GO via endocytosis, rather than by the presence of CD33-positive cells in the liver (i.e. Kupffer cells) as hypothesized in another study.
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In conclusion, these data demonstrate two different GO internalization mechanisms. A CD33-specific mechanism, which is preferentially used at lower GO concentrations, and a CD33-independent mechanism, which occurs in cells with endocytic capacity. Resting cells in the G 0 phase of the cell cycle are not only less efficient in taking up GO but are also less sensitive to the cytotoxic action of calicheamicin. These data provide important mechanistic insight into the clinical observation that GO can also be effective in patients with CD33-negative leukemia. They may in part explain the toxic side effects of GO treatment observed specifically in organs like the liver containing large numbers of cells with endocytic capacity. In addition, our data provide a rationale for the use of GO in the treatment of patients with other hematological malignancies with endocytic capacity.
